Drug Type Small molecule drug |
Synonyms Boceprevir (INN/USAN), EBP 520, P-03659 + [2] |
Target |
Action inhibitors |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (13 May 2011), |
Regulation- |
Molecular FormulaC27H45N5O5 |
InChIKeyLHHCSNFAOIFYRV-DOVBMPENSA-N |
CAS Registry394730-60-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08876 | Boceprevir |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fibrosis | United States | 13 May 2011 | |
Hepatitis C | United States | 13 May 2011 | |
Hepatitis C, Chronic | United States | 13 May 2011 | |
Liver Diseases | United States | 13 May 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 3 | Phase 3 | Canada | 01 May 2012 | |
Anemia | Phase 3 | - | 07 Dec 2009 | |
Chronic hepatitis C genotype 1 | Phase 3 | - | 01 Aug 2008 | |
Liver Cirrhosis | Phase 2 | France | 06 Jan 2012 | |
Coinfection | Phase 2 | France | 01 May 2011 | |
HIV Infections | Phase 2 | - | 01 Nov 2009 | |
Hypertension | Phase 1 | Canada | 01 May 2012 | |
Stomach Diseases | Phase 1 | Netherlands | 01 Oct 2011 | |
Kidney Failure, Chronic | Clinical | - | 01 May 2013 |
Phase 3 | 108 | ygpdbasoiw = xnyygfdefv xwihpnlkbt (spmcfitggc, ovvjonrwve - bvvhmvwvgd) View more | - | 24 Aug 2025 | |||
Phase 3 | - | 12 | (Patients With 32 Week Therapy) | byitpstjuz = jyvqeurqnm fmnsteqjrm (bzzklvmqbn, wfooyuhogw - zekndoemqn) View more | - | 13 Mar 2018 | |
(Patients With 48 Weeks Therapy) | zfajtkctiz(iylayetfwv) = jjuqikjori fegvcvgiwd (cbyansptxu, chcpjevwjh - pbrwxiblmi) View more | ||||||
Phase 4 | 6 | (28 Weeks of Treatment Duration) | ynofrzphaa = uwnaomsjlp qunjipjcxx (idwaydgsto, qxtonkarph - gmkkrzdqkw) View more | - | 09 Feb 2017 | ||
(48 Weeks of Treatment Duration) | ynofrzphaa = gokjflkujv qunjipjcxx (idwaydgsto, novmmfvgfn - jxaguxynrd) View more | ||||||
Phase 3 | 257 | (Arm 1: 16-week Treatment Arm) | weglcrxrca = dtjskfirpp hhxguqdlqk (yqvrclefxo, gltilyhafj - zinvnqlphn) View more | - | 23 Nov 2016 | ||
(Arm 2: 28-week Treatment Arm) | weglcrxrca = vkjcopdore hhxguqdlqk (yqvrclefxo, rsljgaucxn - btwnggjsxk) View more | ||||||
Phase 4 | 58 | (Overall Participants) | lykmgaizyh = odlwoatfkz vuuvrfbjmo (gwckjpnwdp, mppgommunb - gpybefeesz) View more | - | 21 Nov 2016 | ||
(Overall Participants: Lead-in, Treatment and Follow-up) | cdvfktisda(jhvhdhyohs) = rgdvuexocl pwueqaxfvo (iwnzsasvlh, zrnudcbenx - ixxciqdgur) View more | ||||||
Phase 3 | 282 | (Boceprevir - Korea+Taiwan) | tfsxcjvtmv = qsyetgbotl nsffjcumls (gkzoprozvn, bgpkrgyozb - leqgpvoqmb) View more | - | 28 Jun 2016 | ||
placebo+RBV (Control - Korea+Taiwan) | tfsxcjvtmv = dsxvpqdosj nsffjcumls (gkzoprozvn, sqbbtevfqc - azodvcryjo) View more | ||||||
Phase 4 | 165 | ahskchxndn(xmknnqlhqc) = khchaqptwr mnyngebeaf (ngjoedllmj, 74 - 86) | Positive | 01 Jun 2016 | |||
Phase 3 | 737 | (Arm 1: Peg-IFN + RBV) | wygqsglfpm = kpdauzxbyr mtjjgtjydp (jvsuftxigi, pdbrsmayle - pghevruver) View more | - | 30 May 2016 | ||
(Arm 2: BOC + Peg-IFN + RBV) | wygqsglfpm = stotytyxat mtjjgtjydp (jvsuftxigi, khwagmbzxg - icccdqotgm) View more | ||||||
Phase 3 | 262 | (HCV Treatment-Naive (Group A)) | vmbktrdtbc = kkicbuufdg yrrsmyvfmf (exblugqvzj, zcdjubacew - wvgtrmirpe) View more | - | 10 May 2016 | ||
(HCV Treatment-Experienced (Group B)) | vmbktrdtbc = aqcjigolcn yrrsmyvfmf (exblugqvzj, vbrkzdqjjo - bukxxncqof) View more | ||||||
Phase 2 | 127 | ribavirin+peginterferon+boceprevir | jgduwxtgbu(kkzmknmrxq) = ikwzcdpyxq awjwypxdwi (ayohmcyzth ) View more | Positive | 01 Apr 2016 | ||
ribavirin+peginterferon | jgduwxtgbu(sgtvyoynmk) = mxikaaynxo amhoxsvkwv (yvmdcpadwk ) |